Advanced search
Publication Cover
Therapeutic Delivery Volume 1, 2010 - Issue 6
Submit an article Journal homepage
219
Views
0
CrossRef citations to date
0
Altmetric
Review

Intracellular Delivery of RNA-based Therapeutics Using Aptamers

Kristina W Thiel1 Department of Internal Medicine Department of Radiation Oncology375 Newton Rd5202 MERFIowa CityIA52242USA
&
Paloma H Giangrande1 Department of Internal Medicine Department of Radiation Oncology375 Newton Rd5202 MERFIowa CityIA52242USA;2 [email protected]
Pages 849-861 | Published online: 03 Dec 2010

Bibliography

  • Potti A , SchilskyRL, NevinsJR. Refocusing the war on cancer: the critical role of personalized treatment. Sci. Transl Med.2(28), 28cm13 (2010).
  • Hamburg MA , CollinsFS. The path to personalized medicine. N. Engl. J. Med.363(4), 301–304 (2010).
  • Castanotto D , RossiJJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature457(7228), 426–433 (2009).
  • Morris KV . RNA-directed transcriptional gene silencing and activation in human cells. Oligonucleotides19(4), 299–306 (2009).
  • Akashi H , MatsumotoS, TairaK. Gene discovery by ribozyme and siRNA libraries. Nat. Rev. Mol. Cell Biol.6(5), 413–422 (2005).
  • Behlke MA . Chemical modification of siRNAs for in vivo use. Oligonucleotides18(4), 305–320 (2008).
  • Agrawal S , KandimallaER. Antisense and siRNA as agonists of Toll-like receptors. Nat. Biotech.22(12), 1533–1537 (2004).
  • Sioud M . Does the understanding of immune activation by RNA predict the design of safe siRNAs? Front. Biosci.13, 4379–4392 (2008).
  • Schwarze SR , HoA, Vocero-AkbaniA, DowdySF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science285(5433), 1569–1572 (1999).
  • Song E , ZhuP, Lee S-K et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotech.23(6), 709–717 (2005).
  • Kumar P , WuH, McBrideJLet al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448(7149), 39–43 (2007).
  • Morrissey DV , LockridgeJA, ShawLet al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotech. 23(8), 1002–1007 (2005).
  • Urban-Klein B , WerthS, AbuharbeidS, CzubaykoF, AignerA. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.. Gene Ther.12(5), 461–466 (2004).
  • Zimmermann TS , LeeACH, AkincAet al. RNAi-mediated gene silencing in non-human primates. Nature 441(7089), 111–114 (2006).
  • Kim S -S, Garg H, Joshi A, Manjunath N. Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol. Med.15(11), 491–500 (2009).
  • Chu TC , TwuKY, EllingtonAD, LevyM. Aptamer mediated siRNA delivery. Nucl. Acids Res.34(10), e73 (2006).
  • Peer D , ZhuP, CarmanCV, LiebermanJ, ShimaokaM. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc. Natl Acad. Sci. USA104(10), 4095–4100 (2007).
  • Guo S , TschammerN, MohammedS, GuoP. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum. Gene Ther.16(9), 1097–1110 (2005).
  • McNamara JO II, Andrechek ER, Wang Y et al. Cell type-specific delivery of siRNAs with aptamer–siRNA chimeras. Nat. Biotechnol.24(8), 1005–1015 (2006).
  • Zhou J , LiH, LiS, ZaiaJ, RossiJJ. Novel dual inhibitory function aptamer–siRNA delivery system for HIV-1 therapy. Mol. Ther.16(8), 1481–1489 (2008).
  • Dassie JP , Liu X-Y, Thomas GS et al. Systemic administration of optimized aptamer–siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotech.27(9), 839–846 (2009).
  • Zhou J , SwiderskiP, LiHet al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucl. Acids Res. 37(9), 3094–3109 (2009).
  • Pastor F , KoloniasD, GiangrandePH, GilboaE. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature465(7295), 227–230 (2010).
  • Zhou J , RossiJ. Aptamer-targeted cell-specific RNA interference. Silence1(1), 4 (2010).
  • Soutschek J , AkincA, BramlageBet al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432(7014), 173–178 (2004).
  • Nishina K , UnnoT, UnoYet al. Efficient in vivo delivery of siRNA to the liver by conjugation of α-tocopherol. Mol. Ther. 16(4), 734–740 (2008).
  • Muratovska A , EcclesMR. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett.558(1–3), 63–68 (2004).
  • Chiu YL , AliA, ChuCY, CaoH, RanaTM. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol.11(8), 1165–1175 (2004).
  • Tuerk C , GoldL. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science249(4968), 505–510 (1990).
  • Ellington AD , SzostakJW. In vitro selection of RNA molecules that bind specific ligands. Nature346(6287), 818–822 (1990).
  • McNamara JO , KoloniasD, PastorFet al. Multivalent 4–1BB binding aptamers costimulate CD8+T cells and inhibit tumor growth in mice. J. Clin. Invest. 118(1), 376–386 (2008).
  • Burmeister PE , LewisSD, SilvaRFet al. Direct in vitro selection of a 2´-O-methyl aptamer to VEGF. Chem. Biol. 12(1), 25–33 (2005).
  • Rusconi CP , ScardinoE, LayzerJet al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419(6902), 90–94 (2002).
  • Lupold SE , HickeBJ, LinY, CoffeyDS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res.62(14), 4029–4033 (2002).
  • Ruckman J , GreenLS, BeesonJet al. 2´-fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165): Inhibition of receptor binding and VEGF-induced vascular permeability through interacions requiring the exon 7-encoded domain. J. Biol. Chem. 273(32), 20556–20567 (1998).
  • Biesecker G , DihelL, EnneyK, BendeleRA. Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology42(1–3), 219–230 (1999).
  • Healy JM , LewisSD, KurzMet al. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res. 21(12), 2234–2246 (2004).
  • Beielman L , KarpeiskyA, Matulic-AdamicJ, HaeberliP, SweedlerD, UsmanN. Synthesis of 2´-modified nucleotides and their incorporation into hammerhead ribozymes. Nucl. Acids Res.23(21), 4434–4442 (1995).
  • Adler A , ForsterN, HomannM, GoringerHU. Post-SELEX chemical optimization of a trypanosome-specific RNA aptamer. Comb. Chem. High Throughput Screen.11(1), 16–23 (2008).
  • Floege J , OstendorfT, JanssenUet al. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am. J. Pathol. 154(1), 169–179 (1999).
  • Keefe AD , PaiS, EllingtonA. Aptamers as therapeutics. Nat. Rev. Drug Discov.9(7), 537–550 (2010).
  • Keefe AD , CloadST. SELEX with modified nucleotides. Curr. Opin. Chem. Biol.12(4), 448–456 (2008).
  • Thiel KW , GiangrandePH. Therapeutic applications of DNA and RNA aptamers. Oligonucleotides19(3), 209–222 (2009).
  • Nimjee SM , RusconiCP, SullengerBA. Aptamers: an emerging class of therapeutics. Annu. Rev. Med.56, 555–583 (2005).
  • Khaled A , GuoS, LiF, GuoP. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett.5(9), 1797–1808 (2005).
  • Wullner U , NeefI, EllerA, KleinesM, TurMK, BarthS. Cell-specific induction of apoptosis by rationally designed bivalent aptamer–siRNA transcripts silencing eukaryotic elongation factor 2. Curr. Cancer Drug Targets8(7), 554–565 (2008).
  • Farokhzad OC , ChengJ, TeplyBAet al. Targeted nanoparticle–aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA 103(16), 6315–6320 (2006).
  • Zhang L , Radovic-Moreno Aleksandar F, Alexis F et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle–aptamer bioconjugates. ChemMedChem.2(9), 1268–1271 (2007).
  • Dhar S , GuFX, LangerR, FarokhzadOC, LippardSJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug–PLGA–PEG nanoparticles. Proc. Natl Acad. Sci. USA105(45), 17356–17361 (2008).
  • Chen CH , DellamaggioreKR, OuelletteCPet al. Aptamer-based endocytosis of a lysosomal enzyme. Proc. Natl Acad. Sci. USA 105(41), 15908–15913 (2008).
  • Hicke BJ , StephensAW, GouldTet al. Tumor targeting by an aptamer. J. Nucl. Med. 47(4), 668–678 (2006).
  • Borbas KE , FerreiraCSM, PerkinsA, BruceJI, MissailidisS. Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. Bioconjug. Chem.18(4), 1205–1212 (2007).
  • Bates PJ , KahlonJB, ThomasSD, TrentJO, MillerDM. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J. Biol. Chem.274(37), 26369–26377 (1999).
  • Ferreira CSM , MatthewsCS, MissailidisS. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour Biol.27(6), 289–301 (2006).
  • Cerchia L , DucongeF, PestourieCet al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol. 3(4), e123 (2005).
  • Pestourie C , CerchiaL, GombertKet al. Comparison of different strategies to select aptamers against a transmembrane protein target. Oligonucleotides 16(4), 323–335 (2006).
  • Li N , LarsonT, NguyenHH, SokolovKV, EllingtonAD. Directed evolution of gold nanoparticle delivery to cells. Chem. Commun. (Camb)46(3), 392–394 (2010).
  • Chen CB , ChernisGA, HoangVQ, LandgrafR. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc. Natl Acad. Sci. USA100(16), 9226–9231 (2003).
  • Ohuchi SP , OhtsuT, NakamuraY. Selection of RNA aptamers against recombinant transforming growth factor-β type III receptor displayed on cell surface. Biochimie88(7), 897–904 (2006).
  • Kraus E , JamesW, BarclayAN. Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function. J. Immunol.160(11), 5209–5212 (1998).
  • Dey AK , KhatiM, TangM, WyattR, LeaSM, JamesW. An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J. Virol.79(21), 13806–13810 (2005).
  • Khati M , SchumanM, IbrahimJ, SattentauQ, GordonS, JamesW. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2‘F-RNA aptamers. J. Virol.77(23), 12692–12698 (2003).
  • Israeli RS , PowellCT, CorrJG, FairWR, HestonWDW. Expression of the prostate-specific membrane antigen. Cancer Res.54(7), 1807–1811 (1994).
  • Su SL , Huang I-P, Fair WR, Powell CT, Heston WDW. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res.55(7), 1441–1443 (1995).
  • Ni X , ZhangY, DeWeeseTL, LupoldSE. Prostate tumor radiosensitization through PSMA-aptamer-targeted siRNA knock-down of DNA repair pathways. Presented at: 13th Annual Meeting American Society of Gene & Cell Therapy. Washington, DC, USA, 19–22 May 2010.
  • Zhou J , NeffPC, LiuXet al. Systemic administration of dendrimer- and aptamer–siRNA conjugates efficiently suppresses HIV-1 infection. Presented at: 13th Annual Meeting American Society of Gene & Cell Therapy. Washington, DC, USA, 19–22 May 2010.
  • Dove A . An apt approach. Nat. Med.16(3), 258–260 (2010).
  • Dominska M , DykxhoornDM. Breaking down the barriers: siRNA delivery and endosome escape. J. Cell Sci.123(8), 1183–1189 (2010).
  • Shamah SM , HealyJM, CloadST. Complex target SELEX. Acc. Chem. Res.41(1), 130–138 (2008).
  • Caruthers M . Gene synthesis machines: DNA chemistry and its uses. Science230(4723), 281–285 (1985).
  • Thiel KW , ThielWH, LiuXet al. Delivery of chemo-sensitizing siRNAs to HER2-positive breast cancer cells using RNA aptamers. Presented at: 13th Annual Meeting American Society of Gene & Cell Therapy. Washington, DC, USA, 19–22 May 2010.
  • Chu TC , MarksJW III, Lavery LA et al. Aptamer: toxin conjugates that specifically target prostate tumor cells. Cancer Res.66(12), 5989–5992 (2006).
  • Bagalkot V , FarokhzadOC, LangerR, JonS. An aptamer–doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl.45(48), 8149–8152 (2006).
  • Cheng J , TeplyBA, SherifiIet al. Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28(5), 869–876 (2007).
  • Farokhzad OC , JonS, KhademhosseiniA, Tran T-NT, LaVan DA, Langer R. Nanoparticle-Aptamer Bioconjugates. Cancer Research64(21), 7668–7672 (2004).
  • Gu F , ZhangL, TeplyBAet al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl Acad. Sci. USA 105(7), 2586–2591 (2008).
  • Jayaprakash S , WangX, HestonW, KozikowskiA. Design and synthesis of a PSMA inhibitor–doxorubicin conjugate for targeted prostate cancer therapy. ChemMedChem.1(3), 299–302 (2006).
  • Hicke BJ , MarionC, Chang Y-F et al. Tenascin-C aptamers are generated using tumor cells and purified protein. J. Biol.Chem.276(52), 48644–48654 (2001).
  • Santulli-Marotto S , NairSK, RusconiC, SullengerB, GilboaE. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res.63(21), 7483–7489 (2003).
  • Dollins CM , NairS, BoczkowskiDet al. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem. Biol. 15(7), 675–682 (2008).
  • Liu Y , Kuan C-T, Mi J et al. Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biol. Chem.390(2), 137–144 (2008).
  • Rentmeister A , BillA, WahleT, WalterJ, FamulokM. RNA aptamers selectively modulate protein recruitment to the cytoplasmic domain of β-secretase BACE1 in vitro. RNA12(9), 1650–1660 (2006).
  • O‘Connell D , KoenigA, JenningsSet al. Calcium-dependent oligonucleotide antagonists specific for L-selectin. Proc. Natl Acad. Sci. USA 93(12), 5883–5887 (1996).
  • Lee HK , ChoiYS, ParkYA, JeongS. Modulation of oncogenic transcription and alternative splicing by β-catenin and an RNA aptamer in colon cancer cells. Cancer Res.66(21), 10560–10566 (2006).
  • Tanaka Y , AkagiK, NakamuraY, KozuT. RNA aptamers targeting the carboxyl terminus of KRAS oncoprotein generated by an improved SELEX with isothermal RNA amplification. Oligonucleotides17(1), 12–21 (2007).
  • Ulrich H , IppolitoJE, PaganOet al. In vitro selection of RNA molecules that displace cocaine from the membrane-bound nicotinic acetylcholine receptor. Proc. Natl Acad. Sci. USA95(24), 14051–14056 (1998).
  • Daniels DA , SohalAK, ReesS, GrisshammerR. Generation of RNA aptamers to the G-protein-coupled receptor for neurotensin, NTS-1. Anal. Biochem.305(2), 214–226 (2002).
  • Ulrich H , MagdesianMH, AlvesMJM, ColliW. In vitro selection of RNA aptamers that bind to cell adhesion receptors of Trypanosoma cruzi and inhibit cell invasion. J. Biol.Chem.277(23), 20756–20762 (2002).
  • Mallikaratchy P , TangZ, KwameS, MengL, ShangguanD, TanW. Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy µ chain in Burkitt‘s lymphoma cells. Mol. Cell Proteomics6(12), 2230–2238 (2007).
  • Jeon SH , KayhanB, Ben-YedidiaT, ArnonR. A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin. J. Biol.Chem.279(46), 48410–48419 (2004).
  • Ferreira CSM , CheungMC, MissailidisS, BislandS, GariepyJ. Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucl. Acids Res.37(3), 866–876 (2009).
  • Soundararajan S , ChenW, SpicerEK, Courtenay-LuckN, FernandesDJ. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res.68(7), 2358–2365 (2008).
  • Girvan AC , TengY, CassonLKet al. AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin. Mol. Cancer Ther. 5(7), 1790–1799 (2006).
  • Cao Z , TongR, MishraAet al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew. Chem. Int. Ed. Engl. 48(35), 6494–6498 (2009).
  • Shangguan D , CaoZC, LiY, TanW. Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin. Chem.53(6), 1153–1155 (2007).
  • Xiao Z , ShangguanD, CaoZ, FangX, TanW. Cell-specific internalization study of an aptamer from whole cell selection. Chemistry14(6), 1769–1775 (2008).
  • Shangguan D , CaoZ, MengLet al. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J. Proteome Res. 7(5), 2133–2139 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.